Mark K. Bennett
35Patents
7h-index
21Co-inventors
65Inventor score
Filing activity: Mar 15, 2002 → Feb 1, 2019
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7691852B2 | Compounds for enzyme inhibition | Emerging Cross-Sectional Technologies | 49 | Active |
| US8080576B2 | Compounds for enzyme inhibition | Emerging Cross-Sectional Technologies | 32 | Active |
| US8080545B2 | Compounds for enzyme inhibition | Emerging Cross-Sectional Technologies | 31 | Active |
| US8357683B2 | Compounds for enzyme inhibition | Emerging Cross-Sectional Technologies | 29 | Active |
| US8431571B2 | Compounds for enzyme inhibition | Emerging Cross-Sectional Technologies | 28 | Active |
| US7252952B2 | In vivo production of cyclic peptides for inhibiting protein—protein interaction | Physics | 8 | Expired |
| US8609654B1 | Compounds for enzyme inhibition | Emerging Cross-Sectional Technologies | 8 | Active |
| US8895034B2 | Collagen production compound | Human Necessities | 7 | Active |
| US9511109B2 | Combination therapy with peptide epoxyketones | Human Necessities | 5 | Active |
| US7378248B2 | In vivo production of cyclic peptides for inhibiting protein-protein interaction | Chemistry; Metallurgy | 4 | Expired |
| US9040462B2 | In vivo production of cyclic peptides for inhibiting protein-protein interaction | Chemistry; Metallurgy | 4 | Active |
| US7741432B2 | Substrate for Rpn11 enzymatic activity | Physics | 3 | Active |
| US7071190B2 | Inhibitors to tubulin polymerization | Chemistry; Metallurgy | 3 | Expired |
| US10258619B2 | Combination therapy with glutaminase inhibitors and immuno-oncology agents | Chemistry; Metallurgy | 3 | Active |
| US6979549B2 | Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a CLLD8 protein | Emerging Cross-Sectional Technologies | 3 | Expired |
| US7425418B2 | Compounds that modulate processes associated with IgE production | Physics | 2 | Expired |
| US7604951B2 | Method for identifying compounds that modulate RXR associated processes with IgE production | Physics | 1 | Active |
| US8765745B2 | Compounds for enzyme inhibition | Emerging Cross-Sectional Technologies | 1 | Active |
| US7598050B2 | Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a chloride intracellular channel 1 protein | Physics | 1 | Active |
| US7378251B2 | Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a thioredoxin-like 32 kDa protein | Human Necessities | 1 | Expired |
| US7422867B2 | Methods of identifying compounds that modulate IL-4 receptor mediated IgE synthesis utilizing a CLLD8 protein | Emerging Cross-Sectional Technologies | 0 | Active |
| US9657058B2 | Compounds for enzyme inhibition | Emerging Cross-Sectional Technologies | 0 | Active |
| US10940148B2 | Combination therapy with glutaminase inhibitors and immuno-oncology agents | Chemistry; Metallurgy | 0 | Active |
| US9359398B2 | Compounds for immunoproteasome inhibition | Chemistry; Metallurgy | 0 | Active |
| USRE47954E1 | Combination therapy with peptide epoxyketones | General | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.